Medical University of Innsbruck at CTAD 2026

Nov 16–19, 2026 Boston, MA ~1.7k attendees Website

Medical University of Innsbruck takes part in 2 sessions at CTAD 2026 in Boston. Its program spans how asymptomatic amyloid should be labelled and what drives changes in plasma phospho-tau 217 and 181 over time in memory-clinic patients.

Organization	CTAD 2026 Attendance
Medical University of Innsbruck Innsbruck, Austria
	Poster Mon Nov 16 – Tue Nov 17 2:00pm Mon – 5:30pm Tue Is cerebral Aβ42-amyloidosis (CAB42-A) a more appropriate labelling for asymptomatic patients than Alzheimer’s disease? (P183) Prevention and early disease Poster Wed Nov 18 7:15am–5:30pm Factors influencing longitudinal plasma phospho-tau 217 and 181 changes in Alzheimer’s dementia – a memory clinic follow-up study. (P318) Blood and CSF biomarkers

Organization

CTAD 2026 Attendance

Medical University of Innsbruck

Innsbruck, Austria

Poster

Mon Nov 16 – Tue Nov 17
2:00pm Mon – 5:30pm Tue

Is cerebral Aβ42-amyloidosis (CAB42-A) a more appropriate labelling for asymptomatic patients than Alzheimer’s disease? (P183)

Prevention and early disease

Poster

Wed Nov 18
7:15am–5:30pm

Factors influencing longitudinal plasma phospho-tau 217 and 181 changes in Alzheimer’s dementia – a memory clinic follow-up study. (P318)

Blood and CSF biomarkers

Instantly find 20 buyers from Medical University of Innsbruck

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the CTAD Conference. Organization details are derived from CTAD’s published program, poster list and sponsor page. Submit a correction